Table 3 Actual prescribing in relation to recommendations
From: Heart failure guidelines and prescribing in primary care across Europe
Spironolactone in general not to be given in combination with ACE | ACE + spironolactone | ||||
|---|---|---|---|---|---|
Recommendation | Countries (% of total) | Year of publication Range (mean) | (%) | Drug use % patients with OR (95%CI) | |
univariate | multivariate | ||||
All countries* | 10381 (100%) | 6.6 | |||
Warning (Identical) | NL, Cz, F, D, Swe (36,5%) | 1995–1998 (1997) | 5,7 | 0.78 (0.66–0.91) | 0.74 (0.63–.87) |
no warning/no recommendation† | Remaining (63,5%) | 1998 (1998) | 7,2 | 1 | 1 |
β-blockers are indicated only for patients with IDCM (idiopathic dilated cardiomyopathy) | β-blocker | ||||
All countries* | 10381 (100%) | 33.8 | |||
Restricted indication (identical) | Cz, H, CH, UK (28.6%) | 1998 (1998) | 40.4 | 1 | 1 |
No restriction | Remaining† (71.4%) | 1995–1998 (1997) | 31.1 | 0.67 (0.61–0.73) | 0.69 (0.63–0.76) |